General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Key performance indicators

Access to healthcare key performance indicators 2014

Research & Development FTEs1 Value (USD millions)2
Novartis Institute for Tropical Diseases
108
17.0
Novartis Vaccines Institute for Global Health
43
10.0
Novartis Institutes for BioMedical Research neglected disease programs
15
3.0
Pharmaceuticals Development on malaria, tuberculosis and neglected diseases
35
11.8
Total
201
41.8

Patient assistance

Patients reached (thousands)

Value (USD millions)3
Novartis Patient Assistance Foundation, Inc.
61.3
546.9
Glivec patient assistance4
60.7
1 215.2
Tasigna patient assistance4
6.4
184.4
Exjade patient assistance
8.1
31.6
Alcon medical missions5
438.6
41.4
Alcon US patient assistance
9.3
13.1
Malaria/Coartem6
70 027.9
137.4
Leprosy (WHO)
308.3
5.6
Pediatric pneumonia/amoxicillin dispersible tablets7
500.0
0.5
Fascioliasis/Egaten8
233.0
0.1
Emergency relief (medicine donations)
1.9
Total
71 653.6
2 178.1

Health systems strengthening

FTEs

People reached (thousands)9

Patients reached (thousands)

Value (USD millions)2
Novartis Foundation
10
3 560.2
13.1
Novartis research capacity-building programs
6
1.0
5.0
Social Business:11Healthy Family in India, Kenya, Vietnam and Indonesia
529
6 646.0
788.4
Total
545
10 207.2
788.4
18.1

Grand total

746

10 207.2

72 442.0

2 238.0


  1. Full-time equivalent positions and contractors
  2. Operating costs
  3. Wholesale acquisition cost (WAC) plus logistic costs for some programs
  4. Value and patients include donations under shared contribution, co-pay models, and full donation
  5. Retail value for surgical products
  6. Coartem was provided without profit for public sector use and in donor-funded programs such as the Affordable Medicines Facility – malaria (AMFm). During 2014, 70 million Coartem treatments reached patients based on a preliminary analysis of local distribution. Of these, 40 million treatments came from shipments completed in 2013, and 30 million from shipments in 2014. A total of 66 million treatments were shipped in 2014. The Value of these shipments was calculated by multiplying the number of treatments with the average ex-factory price of non-donor-funded Coartem to private-sector purchasers in developing countries minus payments received from public sector and AMFm customers eligible to receive Coartem at the not-for-profit price.
  7. In 2014, Sandoz supplied 10 million dispersible tablets of Amoxicillin 250mg to UNICEF, which provided treatment for at least 500,000 pediatric patients with pneumonia. Using the number of tablets shipped by Sandoz to UNICEF in 2014, value was calculated by subtracting the price at which Sandoz sold the product to UNICEF from the wholesale acquisition cost of Amoxicillin 500mg in West Africa (divided by two to reflect the dosage of 250mg).
  8. Manufacturing cost
  9. Via training and service delivery
  10. Previously known as the Novartis Foundation for Sustainable Development.
  11. People reached via training